Review and management of drug interactions with boceprevir and telaprevir

1 Peg-IFN α/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 Annals of Rheumatic Diseases, April 26, 2013

2 Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States Clinical Infectious Diseases, May 1, 2013

3 Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial Antiviral Therapy , May 16, 2013

4 Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided Therapy Clinical Infectious Diseases, April 30, 2013

5 PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history Expert Review of Anti-infective Therapy, May 7, 2013

6 Major models of HCV infection Future Virology, May 7, 2013    Review Article

7 Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care AIDSmap news, April 30, 2013

8 Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis AIDSmap news, May 1, 2013

9 Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin Antimicrobial Agents and Chemotherapy, May 15, 2013    Review Article